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Abstract
Background: The low-density lipoprotein receptor-related protein 1 (LRP1) plays critical roles in
lipid metabolism, cell survival, and the clearance of amyloid-β (Aβ) peptide. Functional soluble LRP1
(sLRP1) has been detected in circulating human placenta; however, whether sLRP1 is also present
in the central nervous system is unclear.
Results: Here we show that abundant sLRP1 capable of binding its ligands is present in human brain
tissue and cerebral spinal fluid (CSF). Interestingly, the levels of sLRP1 in CSF are significantly
increased in older individuals, suggesting that either LRP1 shedding is increased or sLRP1 clearance
is decreased during aging. To examine potential effects of pathological ligands on LRP1 shedding,
we treated MEF cells with Aβ peptide and found that LRP1 shedding was increased. ADAM10 and
ADAM17 are key members of the ADAM family that process membrane-associated proteins
including amyloid precursor protein and Notch. We found that LRP1 shedding was significantly
decreased in MEF cells lacking ADAM10 and/or ADAM17. Furthermore, forced expression of
ADAM10 increased LRP1 shedding, which was inhibited by ADAM-specific inhibitor TIMP-3.
Conclusion: Our results demonstrate that LRP1 is shed by ADAM10 and ADAM17 and functional
sLRP1 is abundantly present in human brain and CSF. Dysregulated LRP1 shedding during aging
could alter its function and may contribute to the pathogenesis of AD.
Background
Alzheimer's disease (AD) is the most common cause of
dementia in elderly. The central hypothesis of AD is the
amyloid hypothesis which proposes that accumulation of
amyloid-β (Aβ) peptide, a small peptide with a high pro-
pensity to form aggregates in the brain, is the primary fac-
tor driving AD pathogenesis [1-3]. The low-density
lipoprotein receptor-related protein 1 (LRP1) is a multi-
functional lipoprotein receptor which recognizes over 30
ligands [4,5]. LRP1 was shown to bind to apolipoprotein
E (apoE) [6] and Aβ, both of which play important roles
in the pathogenesis of AD. It has been suggested that
decreased clearance of Aβ from brain and CSF is the main
cause of Aβ accumulation in sporadic AD [7]. LRP1 plays
critical roles in Aβ clearance and neuronal survival [8,9].
Aβ has been shown to initially form a complex with LRP1
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ligands, apoE and α2-macroglobulin (α2M), and then the
complex binds to LRP1. LRP1-ligand complexes are then
internalized to late endosomes after which they can either
be delivered to lysosomes for subsequent degradation or
be targeted for transcytosis across the BBB into the plasma
[8]. Furthermore, Zlokovic and colleagues have provided
evidence showing that Aβ can be transported across the
BBB and be cleared from the brain after directly binding
to LRP1 [8]. In neurons, a chimeric receptor that contains
the intracytoplasmic tail of LRP1 promotes cell survival by
preventing translocation of activated JNK to the nucleus
[9]. Interestingly, it has been reported that the brains of
AD patients had significantly lower LRP1 levels than that
of age-matched controls and that LRP1 levels are
decreased substantially with age in the brains of normal
individuals [10].
LRP1 is synthesized as a precursor that migrates on SDS-
gel with an apparent molecular size of 600 kD [11]. En
route to the cell surface, LRP1 is cleaved into two subunits
of 515 kD and 85 kD. LRP1-515 remains anchored to the
membrane through noncovalent association with the
transmembrane subunit, LRP1-85 [11]. The LRP1-515
contains multiple, Ca2+-dependent ligand binding
domains. It has been reported that the presence of a solu-
ble form of LRP1 (sLRP1) circulates in human plasma
with electrophoretic mobility identical to that of the
LRP1-515, which was recognized by anti-LRP1-515 anti-
bodies and bound the LRP1 ligands a2M and the receptor-
associated protein (RAP) [12,13]. The physiological sig-
nificance of LRP1 ectodomain shedding remains unde-
fined and the presence of sLRP1 in the central nervous
system is unclear. Here we show that abundant sLRP1,
capable of binding its ligands, is present in human brain
tissue and cerebral spinal fluid (CSF). Interestingly, the
levels of sLRP1 in CSF are significantly increased in older
individuals. We also found that Aβ42 increases LRP1
shedding. Furthermore, LRP1 shedding was significantly
decreased in MEF cells lacking ADAM10 and/or ADAM17.
Together our results demonstrate that LRP1 shedding is
regulated by ADAM10 and ADAM17 and functional
sLRP1 is abundantly present in human brain tissues and
CSF. Dysregulated LRP1 shedding during aging could alter
its function and may contribute to the pathogenesis of
AD.
Results
sLRP1 is present in human CSF and brain tissue, and the 
levels of sLRP1 in CSF are significantly increased in older 
individuals
sLRP1 levels were measured in the CSF of normal controls
and AD patients by Western blot (Figure 1A) and RAP lig-
and blot (Figure 1B). As shown in Figure 1A and 1B, the
high molecular weight protein appears to be structurally
and functionally related to human LRP1-515, as it is rec-
ognized by an anti-LRP antibody and binds to RAP in the
RAP ligand blot. Furthermore, abundant LRP1 fragments
are detected by LRP1 antibody (Figure 1A), some of which
are capable of binding RAP (Figure 1B). Interestingly,
both intact LRP1-515 and LRP1 fragments were signifi-
cantly increased in older individuals (90 years old group)
of both control and AD groups as compared to younger
individuals (70 years old group) (Figure 1C), suggesting
that either LRP1 shedding is increased or sLRP1 clearance
is decreased during aging. However, there is no significant
difference in sLRP1 levels between age-matched controls
and AD patients.
The sLRP1 levels were also analyzed in human brain tissue
(from 85 years old non-AD individual) by Western blot.
Cortex and hippocampus of human brain tissue were sep-
arated into membrane and soluble fractions, and were
blotted with LRP1 antibody. As shown in Figure 2, sLRP1
was detected in the soluble fraction, suggesting that sLRP1
is also present in human brain tissue. The LRP1 fragments
which showed in CSF samples could not be detected in
human brain tissue, suggesting that intact LRP1-515 could
be further cleaved by some enzymes in CSF.
Aβ42 increases LRP1 shedding
To examine potential effect of pathological ligands on
LRP1 shedding, mouse embryonic fibroblast (MEF) cells
were treated with Aβ42 or vehicle control for 48 h. Media
and cell lysates were collected and blotted with two LRP1
antibodies [9,14,15] to detect either the extracellular
LRP1-515 subunit or the transmembrane LRP1-85 subu-
nit. LRP1-515 detected in the media represents sLRP1. The
ratios of sLRP1 in the media and intact LRP1 in the lysates
were compared among two treatments. We found that the
relative sLRP1 levels are significantly increased after Aβ42
treatment (Figure 3). LRP1 shedding is significantly
decreased in MEF cells lacking ADAM10 or ADAM17.
ADAM10 and ADAM17 are members of the ADAM metal-
loprotease family and play critical roles in ectodomain
shedding of several transmembrane proteins including
APP [3]. To understand how LRP1 is shed, LRP1 and
sLRP1 levels were examined in ADAM17-KO and
ADAM10-KO MEF cells. After one day in culture, media
and cell lysates were collected and blotted with two LRP1
antibodies to detect either LRP1-515 or LRP1-85. LRP1-
515 detected in the media represents sLRP1. The ratios of
sLRP1 in the media and LRP1-85 in the lysates were com-
pared among WT and KO cell types. We found that the rel-
ative sLRP1 levels were significantly decreased in
ADAM17-KO and ADAM10-KO MEF cells (Figure 4). We
also found that the cell associated LRP1-515 and LRP1-85
are both increased (Figure 4), indicating that LRP1 expres-
sion may be increased in the absence of ADAM10 or
ADAM17.
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Over-expression of ADAM10 or ADAM17 increases LRP1 
shedding, which is inhibited by ADAM-specific inhibitor 
TIMP-3
Because TIMP-3 is a natural inhibitor of matrix metallo-
proteinases [16], it was used to inhibit ADAM activity in
this study. To examine whether forced expression of
ADAM10 or ADAM17 increases LRP1 shedding, CHO
LRP1-null cells were transiently co-transfected with a HA-
tagged LRP1 minireceptor (mLRP4) [17] together with
RAP, ADAM10, ADAM17, and/or TIMP-3. The levels of
sLRP1 were then measured by Western blot using HA anti-
body [17]. As shown in Figure 5, over-expression of
ADAM10, but not ADAM17, enhanced the shedding of
mLRP4. This may suggest that endogenous ADAM17
might be sufficient for the shedding of mLRP4. Over-
expression of ADAM10 or ADAM17 together with TIMP-3
completely eliminated the shedding of mLRP4. These
results suggest that mLRP4 can be shed by ADAM10 and
ADAM17, which are inhibited by TIMP-3.
Discussion
LRP1 belongs to the low-density lipoprotein receptor fam-
ily, the members of which share many structural and func-
tional characteristics. The LRP1-515 subunit of LRP1
contains multiple Ca2+-dependent ligand binding
domains and is bound to the membrane-spanning LRP1-
85 subunit. Functional soluble LRP1 (sLRP1) has been
detected in circulating human placenta; however, whether
sLRP1 is also present in the central nervous system is
unclear. Here we show that sLRP1 is abundantly present
in human CSF in the forms of LRP1-515 and LRP1 frag-
ments, which are recognized by LRP1 antibody and bind
to the LRP1 ligand RAP. In human brain tissues, sLRP1 is
also detected in the soluble fractions of both cortex and
sLRP1 is present in human cerebral spinal fluid (CSF) and the levels of sLRP1 in CSF are significantly increased in older individ-ualsFigure 1
sLRP1 is present in human cerebral spinal fluid (CSF) and the levels of sLRP1 in CSF are significantly increased 
in older individuals. sLRP1 levels were measured in CSF of normal controls and AD patients by Western blot (A) and RAP 
ligand blot (B). (C) Band intensities of Western blot (A) were analyzed by densitometry (n = 8).
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hippocampus. The precise nature of the LRP1 fragments
needs to be further characterized by mass spectrometry
using highly purified sLRP1.
Kang et al. found that the brains of AD patients had signif-
icantly lower levels of LRP1 than that of age-matched con-
trols. Moreover, they also showed that in the brains of
normal individuals, LRP1 levels are decreased substan-
tially with age. The changes in LRP1 levels could be due to
LRP1 shedding in the brain. We tested this hypothesis by
comparing sLRP1 levles in normal controls and AD
patients and found that the levels of sLRP1 in CSF are sig-
nificantly increased in older individuals. This suggests that
either LRP1 shedding is increased or sLRP1 clearance is
decreased during aging. However, we did not detect signif-
icant differences in sLRP1 levels between normal controls
and AD patients. This was somewhat surprising as we
found that Aβ42 significantly increases LRP1 shedding in
vitro. It is possible that increased LRP1 shedding in AD
leads to its deposition in amyloid plaques [18] rather than
distribution to CSF. Further studies are required to test
this hypothesis.
The detection of sLRP1 in conditioned medium of MEF
cells provides a model system for elucidating the mecha-
nism of LRP1 shedding. ADAM family members are
involved in ectodomain shedding of various cell surface
proteins such as growth factors, receptors and their lig-
ands, cytokines, and cell adhesion molecules [19]. Among
them, ADAM10 and ADAM17, also referered to as α-secre-
tase, are the sheddases for APP. And Hoe et al. found that
TIMP3 inhibited the α-secretase (ADAM10 and ADAM17)
cleavage of ApoER2, an apoE receptor [20]. In the present
study using ADAM10-KO and ADAM17-KO MEF cells, we
found that ADAM10 and ADAM17 are also involved in
LRP1 shedding. Furthermore, forced expression of
ADAM10 significantly increased the shedding of LRP1,
which was inhibited by TIMP3, a natural inhibitor of
ADAMs. These results demonstrate that LRP1 is likely
shed by ADAM10 and ADAM17. Previous studies have
already shown that LRP1 can also be cleaved by beta site
of APP-cleaving enzyme (BACE1), also referered to as β-
secretase, to release secreted LRP1 in the medium [21],
suggesting that BACE1 cleavage may also contribute to the
production of sLRP1.
The identification of the soluble forms of LRP1 in human
CSF and brain tissue introduces a new dimension into the
biology of this unique molecule, especially in neuropa-
thology and aging. Further studies are required to under-
stand the structures of the LRP1 fragments and establish
their physiological role in the brain and CSF. Dysregu-
lated LRP1 shedding during aging could alter its function
and may contribute to the pathogenesis of AD.
Conclusion
Functional sLRP1 is abundantly present in human brain
and CSF, and is likely increased during aging. LRP1 shed-
ding is mediated by ADAM10 and ADAM17 and is up-reg-
ulated by Aβ42. Increased LRP1 shedding during aging
could contribute to the pathogenesis of AD.
Methods
Materials
Human recombinant RAP was expressed in a glutathione
S-transferase expression vector and isolated as described
previously [22]. All tissue culture media and serum were
from Sigma. In-house anti-LRP1 has been described previ-
ously [9,14,15]. Peroxidase-labeled anti-mouse antibody
and ECL system were from GE Healthcare. Human Aβ42
was from BACHEM. Human CSF samples are from AD
patient of Braak Stage of 6 and normal controls and 8
samples from each group were analyzed.
Cell culture
MEF cells were cultured in Dulbecco's modified Eagle's
medium (DMEM) supplemented with 10% fetal calf
serum in humidified air with 5% CO2 at 37°C. CHO
sLRP1 is present in human brain tissuesFigure 2
sLRP1 is present in human brain tissues. Cortex and 
hippocampus of human brain tissue were separated into 
membrane and soluble fractions, and were blotted wih LRP1 
antibody. sLRP1 was detected in both hippocampus and cor-
tex.
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LRP1-null cells were cultured in Ham's F12 medium sup-
plemented with 10% fetal calf serum in humidified air
with 5% CO2 at 37°C.
Transfection
CHO LRP1-null cells were transfected with the appropri-
ate cDNAs: LPR1 minireceptor (mLRP4), RAP, ADAM10,
ADAM17 and/or TIMP3. Twenty-four hours after transfec-
tion, media was collected and concentrated, and cells
were rinsed, gently scraped into PBS (pH 7.4), and pel-
leted. Cells were then lysed in lysis buffer, and the lysate
and concentrated media were used for Western blot.
Preparation of soluble and membrane fractions from 
human brain tissue
Preparation of soluble and membrane fractions has been
described before [23]. Briefly, brain tissues were homoge-
nized in ice-cold homogenization buffer (20 mM Tris(pH
8.0), 150 mM NaCl, 1 mM CaCl2, with EDTA-free Com-
plete proteinase inhibitors) using a Polytron homoge-
nizer. After two-low speed spins (1,500 × g and 10,000 ×
g), the homogenate was centrifuged 30 min at 100,000 ×
g at 4°C to separate the membrane fraction (pellet) from
the soluble fraction. The pellet was resuspended in 50 mM
Tris (pH8.0), 80 mM NaCl, 2 mM CaCl2, with EDTA-free
Complete proteinase inhibitors. Triton X-100 was then
added to both the membrane and soluble fraciton to a
final concentration of 1%. The membrane fraction was
passed through a 28-gauge needle and cleared by a second
centrifugation at 100,000 × g to remove insoluble mate-
rial.
Western blotting and RAP ligand blotting
Cell and tissue samples were lysed on ice in lysis buffer
(phosphate-buffered saline containing 1% Triton X-100,
Aβ increases LRP1 sheddingFigure 3
Aβ increases LRP1 shedding. MEF cells were treated with vehicle control or 1 μM Aβ42 for 48 h. Media and cell lysates 
were blotted with two LRP1 antibodies to detect either the extracellular LRP1-515 subunit or the transmembrane LRP1-85 
subunit. LRP1-515 detected in the media represents sLRP1 and is increased with Aβ42 treatment. Band intensities were ana-
lyzed by densitometry from triplicate samples. The ratios of sLRP1 in the media and LRP1-85 in the lysates were compared 
among three treatments. Note, the relative sLRP1 levels were significantly increased after Aβ42 treatment.
LRP1 shedding is significantly decreased in MEF cells lacking ADAM10 or ADAM17Figure 4
LRP1 shedding is significantly decreased in MEF cells 
lacking ADAM10 or ADAM17. LRP1 and sLRP1 levels 
were analyzed by Western blots as in Figure 3. Band intensi-
ties were analyzed by densitometry from triplicate samples. 
The ratios of sLRP1 in the media and LRP1-85 in the lysates 
were compared among three cell types. Note, the relative 
sLRP1 levels were significantly decreased in ADAM17-KO 
and ADAM10-KO MEF cells.
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1 mM phenylmethylsulfonyl fluoride and protease inhib-
itor cocktail from Roche). CSF samples were directly
mixed with sample buffer. Protein concentration was
determined in each sample using a Protein Assay kit (Bio-
Rad). Equal amount of protein was used for SDS-PAGE.
Immunoreactive bands were visualized by enhanced
chemiluminescence and exposed to film. In RAP ligand
blotting, blots were probed with 20 nM RAP for 1 h at
room temperature, and then with RAP-specific antibody.
For densiometric analyses, immunoreactive bands were
scanned using a Kodak Digital Science DC290 Zoom cam-
era and quantified using Kodak Digital Science image
analysis software.
Statistical Analysis
All quantified data represent an average of at least tripli-
cate samples. Error bars represent standard deviations.
Statistical significance was determined by Student's t-test
and P < 0.05 was considered significant.
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